SOA-101

N/A

Report date: 2026/03/23 17:56:22

Base Information

Drug NameSOA-101

Drug Alias NameSOA101SOA-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT-cell surface glycoprotein CD3 epsilon chain modulatorsProgrammed death-ligand 1 antagonistsHLA class I histocompatibility antigen, alpha chain G inhibitors

TargetsT-cell surface glycoprotein CD3 epsilon chainProgrammed death-ligand 1HLA class I histocompatibility antigen, alpha chain G

Therapy Area/IndicationsSolid tumoursLung NeoplasmsBrain Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesShine-On BioMedical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShine-On BioMedical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursLung NeoplasmsBrain Neoplasms +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A